This post was originally published on The Economic Times
BENGALURU: Biomoneta Research Private Limited, a Bengaluru-based healthtech company, announces it has received US Food and Drug Administration (FDA) 510(k) Class II clearance for the Biomoneta® Avata Rx Medical Recirculating Air Cleaner. The clearance enables Biomoneta to enter the US and healthcare market with its globally patented ZeBox technology.
The Avata Rx system is built on Biomoneta’s proprietary ZeBox platform, which represents a fundamentally different approach to air decontamination compared to conventional systems. Instead of relying on HEPA filters, UV radiation, or ozone-based chemical processes, ZeBox employs nanomaterials and advanced power electronics to extract naturally charged microbes from the air through a non-ionizing electric field. These microbes are then captured on engineered microbicidal surfaces, where they are eliminated. Independent third party laboratory testing and published research have demonstrated more than 99.9999 percent efficacy in eliminating airborne pathogens, including SARS-CoV-2, H1N1, and even Mycobacterium tuberculosis.
Arindam Ghatak, Co-founder and CEO, Biomoneta Research, said in a statement, “This FDA clearance validates everything our team has worked toward over the last eleven years. We set out to prevent hospital-acquired infections by creating truly germ-free air zones. This milestone now enables us
— Read the rest of this post, which was originally published on The Economic Times.
